These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11028934)

  • 1. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease.
    Liu GG; Hay J
    Pharm Res; 2000 Aug; 17(8):911-9. PubMed ID: 11028934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
    Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
    Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
    Rose DN; Sacks HS
    AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
    Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
    Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
    Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
    Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS.
    Rachlis A; Smaill F; Walker V; Hotchkies L; Jones A
    Pharmacoeconomics; 1999 Jul; 16(1):71-84. PubMed ID: 10539123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
    Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
    Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost advantages of oral drug therapy for managing cytomegalovirus disease.
    Somerville KT
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S9-12. PubMed ID: 14686229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients.
    Sullivan SD; Mozaffari E; Johnson ES; Wolitz R; Follansbee SE
    Clin Ther; 1996; 18(3):546-58. PubMed ID: 8829030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation.
    Jung C; Engelmann E; Borner K; Offermann G
    Transplant Proc; 2001; 33(7-8):3621-3. PubMed ID: 11750538
    [No Abstract]   [Full Text] [Related]  

  • 16. Costs and consequences of cytomegalovirus disease.
    Schnitzler MA
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
    Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
    JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of cytomegalovirus infection after liver transplantation.
    Kim WR; Badley AD; Wiesner RH; Porayko MK; Seaberg EC; Keating MR; Evans RW; Dickson ER; Krom RA; Paya CV
    Transplantation; 2000 Feb; 69(3):357-61. PubMed ID: 10706042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis.
    Davies L; Maynard A
    Int J STD AIDS; 1996 Oct; 7(6):415-21. PubMed ID: 8940670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.